Correlation Revealed between Gemtuzumab-Ozogamicin Efficacy and CD33+ Expression in AML Primary Samples through a Novel AML in Vitro Model
Mara Gilardi(Champions Oncology (United States)), Michael Ritchie(Champions Oncology (United States)), Brandon Walling(Champions Oncology (United States)), M Zipeto(Champions Oncology (United States)), Paolo Schiavini(Champions Oncology (United States)), Stefano Cairo, Vaishnavi Sambandam(National Comprehensive Cancer Network), Garima Kaushik
Cited by 1
Related Papers
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
|EMBO Molecular Medicine|2018|271
TAK1 Suppresses a NEMO-Dependent but NF-κB-Independent Pathway to Liver Cancer
|Cancer Cell|2010|220
Molecular genetics and cellular events of K-Ras-driven tumorigenesis
|Oncogene|2017|95